Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Literal federal measure citations: H.R. 7389
2026 · 1st Quarter (Jan 1 - Mar 31)
INSTITUTE FOR GENE THERAPIES
Filed by JEFFREY J. KIMBELL & ASSOCIATES, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- JEFFREY J. KIMBELL & ASSOCIATES, INC.
- Filing UUID
- 30cf44a6-ba39-4fc9-b472-71a0d6a1a4c4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.